North America Point Of Care Poc Drug Abuse Testing Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 558.70 Million |
 Market Size (Forecast Year) |
USD 804.35 Million |
 CAGR |
% |
| Major Markets Players |
北美即时诊断 (POC) 药物滥用检测市场，按药物类型（安非他明、阿片类药物、大麻素、可卡因、巴比妥类药物、苯二氮卓类药物、美沙酮、苯环利定、三环类抗抑郁药等）、产品（设备和消耗品及配件）、处方（非处方检测和处方检测）、样品类型（尿液、唾液、血液、头发、呼吸等）、检测类型（随机检测、事后检测和禁欲测试）、应用（医疗筛查、工作场所筛查、执法和刑事司法、疼痛管理、药物滥用治疗和康复、父母或家庭药物检测、体育和田径检测、学校和教育机构的药物筛查等）、最终用户（医疗机构、雇主、政府机构等）、分销渠道（直接招标、零售等）- 行业2031 年趋势和预测。
北美即时诊断（POC）药物滥用检测市场分析及规模
市场增长的驱动因素包括人们对药物滥用预防和管理的认识和重视程度不断提高，以及对在各种环境中快速准确的药物检测的需求不断增长。推动市场增长的关键因素包括药物滥用率上升、工作场所药物检测的严格监管要求以及 POC 检测技术的进步，这些技术提高了准确性和用户便利性。此外，不同人群中药物滥用障碍的患病率不断上升，这也推动了对有效且易于获取的药物检测解决方案的需求。
北美即时诊断 (POC) 药物滥用检测市场涵盖一系列诊断技术和解决方案，旨在在护理地点而非传统实验室环境中检测个人系统中是否存在非法物质或管制药物。这些测试可提供快速的现场结果，这对于在医疗机构、急诊室、工作场所甚至家庭环境等各种环境中及时做出决策和干预至关重要。该市场包括用于检测尿液、唾液、血液和其他生物样本中药物的设备和检测试剂盒。
Data Bridge Market Research 分析，北美即时诊断 (POC) 药物滥用检测市场规模预计将从 2023 年的 5.587 亿美元增至 2031 年的 8.0435 亿美元，在 2024 年至 2031 年的预测期内，复合年增长率为 4.8%。
|
报告指标 |
细节 |
|
预测期 |
2024 至 2031 年 |
|
基准年 |
2023 |
|
历史岁月 |
2022（可定制 2016-2021） |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
药物类型（安非他明、阿片类药物、大麻素、可卡因、巴比妥类药物、苯二氮卓类药物、美沙酮、苯环利定、三环类抗抑郁药等）、产品（设备、耗材和配件）、处方（非处方检测和处方检测）、样品类型（尿液、唾液、血液、头发、呼吸等）、检测类型（随机检测、事后检测和戒断检测）、应用（医疗筛查、工作场所筛查、执法和刑事司法、疼痛管理、药物滥用治疗和康复、家长或家庭药物检测、体育运动检测、学校和教育机构药物筛查等）、最终用户（医疗机构、雇主、政府机构等）、分销渠道（直接招标、零售等） |
|
覆盖国家 |
美国、加拿大、墨西哥 |
|
涵盖的市场参与者 |
雅培实验室、Quest Diagnostics Incorporated、赛默飞世尔科技、Bio-rad Laboratories、安捷伦科技、Advacare Pharma、Cliawaived inc. 等。 |
市场定义
即时 (PoC)药物滥用检测是指在诊所或急诊室等护理场所检测人体系统中是否存在药物或其代谢物的快速筛查方法。这些检测可快速提供结果，从而及时做出治疗或干预决策。即时检测通常涉及尿液、唾液或血液样本，对于监测药物使用、确保患者安全以及促进获得适当的支持服务至关重要
北美即时诊断（POC）药物滥用检测市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。以下内容将详细讨论所有这些内容：
驱动程序
- 药物滥用率上升
涉及阿片类药物、大麻素和安非他明的药物滥用在地区范围内不断增长，造成了一场公共卫生危机，需要立即采取可扩展的解决方案。医疗保健提供者、执法机构和雇主越来越依赖 POC 药物检测，因为它提供快速、准确和现场检测，这对于管理药物滥用的后果至关重要。
在医疗保健领域，快速检测药物滥用对于及时干预至关重要，尤其是在紧急情况或康复中心。在执法领域，现场检测个人的能力可以加快决策速度并加强遏制毒品犯罪的力度。同样，工作场所也采用 POC 药物检测来维持无毒环境、减少责任并遵守安全法规。
POC 检测设备的技术进步进一步满足了人们对快速、可靠检测方法日益增长的需求。这些设备越来越便携、用户友好，并且能够检测多种物质，非常适合在非实验室环境中使用。
例如，
- 2024 年 1 月，根据 NCBI 发表的一篇文章，阿片类药物使用障碍 (OUD) 影响了全球超过 1600 万人，其中包括美国的 210 万人，导致该地区每年有超过 12 万人死亡。阿片类药物的使用和依赖性很高，高达 50% 的长期阿片类药物使用者符合 OUD 标准。阿片类药物相关问题发病率的上升推动了对有效药物检测解决方案的需求，从而推动了北美即时诊断 (POC) 药物滥用检测市场的增长
- 2023 年 8 月，根据世卫组织发表的一篇文章，2019 年，该地区约有 600,000 人死亡与吸毒有关，其中约 80% 与阿片类药物有关。其中，约 125,000 人死于阿片类药物过量，而非致命性过量则更为常见。阿片类药物过量病例的增加归因于用于慢性疼痛管理的阿片类药物供应增加以及非法市场上存在强效阿片类药物。在美国，2019 年药物过量死亡总数为 70,630 人，其中约一半与合成阿片类药物有关。
家庭和家长药物检测试剂盒的增长
家用非处方药物检测试剂盒的需求不断增长，这反映出消费者对监控药物滥用的隐私和便利的强烈偏好。家长越来越多地采用这些试剂盒来检测和预防青少年滥用药物，而个人则出于个人原因选择自我检测。
技术进步催生了更准确、更可靠、更易于使用的药物检测产品，使消费者能够在家中私下进行检测，而无需专业人员协助。这种便利减少了与药物检测相关的耻辱感，促进了这些解决方案的更广泛采用。家庭检测试剂盒现在更加灵敏，能够检测多种药物，提供与实验室测试相当的结果。
人们对药物滥用的认识不断提高，以及这些试剂盒可通过药店和在线平台轻松获得，这些都促进了市场的增长。人们越来越倾向于使用唾液或尿液测试等在家中简单易用的非侵入性样本采集方法，这也进一步支持了这一趋势。
例如，
- 2023 年 11 月，根据 DNA Forensics Laboratory Pvt. Ltd. 发表的一篇文章，近年来，家用药物检测试剂盒因其便利性和易用性而越来越受欢迎。这些试剂盒使个人能够在家中私下进行药物测试，通常包括测试条或收集设备以及有关样本收集和结果解释的明确说明。这种家庭测试趋势凸显了“家庭和父母药物检测试剂盒的增长”，并推动了对此类产品的需求。对私密和便捷的药物检测解决方案的日益偏好推动了北美即时诊断 (POC) 药物滥用检测市场的扩张。
总之，家庭和父母药物检测试剂盒的需求不断增长，为消费者提供了私密、方便、可靠的药物滥用监测选项，推动了 POC 药物滥用检测市场的显著增长，促进了该领域的扩张。
机会
- 意识的提高和药物检测运动
人们对药物滥用危害的认识不断提高，再加上强有力的公共卫生运动和政府支持，为北美即时诊断 (POC) 药物滥用检测市场提供了巨大的增长机会。随着社会越来越认识到药物滥用的有害影响，对可获得且有效的检测解决方案的需求也日益增长。公共卫生运动通常由政府和非政府组织牵头，在教育社区了解早期发现和干预的重要性方面发挥着至关重要的作用。这些举措不仅扩大了药物滥用问题的知名度，而且还提倡使用即时诊断作为预防措施。此外，政府通过资金和政策制定提供的支持通过促进监管框架来提高即时诊断药物检测解决方案的可及性，这些框架有助于在工作场所、学校和公共卫生计划等各种环境中采用这些技术。提高认识和战略支持的结合营造了有利于市场扩张的环境，推动创新并增加先进测试解决方案的可用性以满足社会不断变化的需求。
- 2023年12月，根据大伦敦政府发表的文章，英国政府为这项任务拨款154万美元，重点检测14种不同的药物。随着英国意识的提高和政府的积极举措，英国对刑满释放人员实施了随机强制性药物检测，旨在降低犯罪率。这一举措凸显了英国致力于解决药物滥用及其对犯罪行为的影响的决心，反映了英国为提高公众安全和福祉所做的更广泛努力。
- 2021年7月，据澳大利亚联邦政府和卫生与老年护理部发表的文章称，澳大利亚政府启动了“国家冰毒行动战略”，其中包括投入大量资金加强即时检测（POC）药物滥用。该举措旨在通过为执法人员和医疗保健提供者提供更方便、更准确的药物检测工具，遏制日益增长的甲基苯丙胺（俗称“冰毒”）的使用。该战略还侧重于扩大即时检测在偏远和农村地区的可用性，确保全国各地的社区都能从及时有效的药物检测和干预措施中受益。
因此，日益增强的意识、积极的公共卫生运动和强有力的政府支持相结合，将极大地有利于北美即时诊断 (POC) 药物滥用检测市场。这种动态环境不仅促进了药物检测技术的采用，还鼓励开发更复杂、更易于获取的解决方案。随着这些因素的持续，即时诊断药物滥用检测的未来前景光明，创新机会增多，市场覆盖面更广，公共卫生成果得到改善。
克制/挑战
- 测试成本高昂
开发可靠且准确的 POC 药物滥用检测非常复杂，通常需要先进的技术、专门的材料和严格的验证流程，所有这些都会导致生产成本上升。严格的监管要求进一步增加了这些成本，因为确保符合国际标准需要进行广泛的测试、质量控制和记录，从而增加了总体费用。此外，需要持续进行研究和开发以跟上新出现的药物滥用模式并提高这些检测的敏感性和特异性，这进一步推高了成本。对于医疗保健提供者来说，将这些检测解决方案整合到他们的实践中所需的高额前期投资可能是令人望而却步的，尤其是对于预算有限的小型诊所或组织而言。尽管 POC 药物滥用检测在速度和便利性方面具有潜在优势，但这种财务负担可能会阻碍其采用。这种情况在低收入和中等收入国家更为严重，因为这些国家的医疗保健预算已经很紧张，而 POC 检测的额外成本可能会成为实施的障碍，限制市场在这些地区的扩张。此外，高昂的成本还会导致医疗保健服务不均等，因为只有资金充足的机构才可能负担得起这些先进的检测方法，而弱势群体则得不到足够的检测和护理。这一挑战不仅是一个财务问题，也是一个道德问题，因为无法提供负担得起的检测解决方案会破坏更广泛打击药物滥用的努力。
例如，
- 2023 年 5 月，根据美国国家医学图书馆发表的一篇文章，由于大多数 POCT 设备都是一次性的，因此与传统实验室检测相比，POC 检测的个人成本更高，这增加了总体费用
- 2024 年 1 月，根据 Checkr. 发表的一篇文章，综合实验室药物检测的费用可能超过 500 美元。现场检测费用通常在 20 至 40 美元之间，但需要实验室确认，这可能会推高价格，最低为 50 美元，具体价格取决于检测类型和筛查物质。大量检测可能会降低每次检测的平均成本，但总体费用仍然可能相当可观
因此，POC 药物滥用检测的高成本为其广泛采用造成了重大障碍，限制了可及性，尤其是在资源匮乏的地区。这一财务挑战不仅阻碍了市场增长，还加剧了医疗保健不平等，使许多人无法及时有效地接受药物滥用检测，预计这将成为未来市场增长的挑战。
最新动态
- 2024 年 8 月，雅培于 2024 年 8 月 7 日宣布与美敦力建立北美合作伙伴关系，将雅培先进的 FreeStyle Libre 连续血糖监测 (CGM) 技术与美敦力的胰岛素输送系统相结合。此次合作旨在实现自动胰岛素调整并改善糖尿病管理，使全球超过 1100 万人受益。财务条款未披露
- 2024 年 3 月，雅培将与皇家马德里和皇家马德里基金会的合作延长至 2026-2027 赛季，继续担任其北美健康科学和营养合作伙伴。自 2021 年以来，雅培提供了超过 25,000 小时的营养教育，并为 3,000 多名儿童筛查了营养不良情况
- 2023 年 8 月，SSM Health 与西门子医疗合作，促进医疗公平并促进医疗服务不足社区的劳动力发展。与 SSM Health 的合作将使西门子医疗受益，扩大其市场影响力、提高其技术知名度、促进长期增长并提升其在医疗保健领域的声誉
- 2024 年 2 月，罗氏与 PathAI 达成合作协议，以扩展伴随诊断的数字病理学能力。此次合作为罗氏提供了 PathAI 先进的 AI 技术，以改进伴随诊断。它确保了独家、量身定制的解决方案并加速了算法开发，同时使罗氏能够继续开发自己的诊断
- 2023 年 11 月，罗氏推出新一代 qPCR 系统，以推动分子诊断的临床需求并应对公共卫生挑战。罗氏的新一代 qPCR 系统提升了其市场地位，满足了临床和公共卫生需求，并在展示其对创新的承诺的同时开辟了新的收入机会
北美即时诊断（POC）药物滥用检测市场范围
北美即时诊断 (POC) 药物滥用检测市场根据药物类型、产品、处方、样本类型、检测类型、应用、最终用户和分销渠道分为八个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
药物类型
- 安非他明
- 鸦片类药物
- 大麻素
- 可卡因
- 巴比妥类药物
- 苯二氮卓类
- 美沙酮
- 苯环利定
- 三环类抗抑郁药
- 其他的
根据药物类型，市场分为安非他明、大麻素、阿片类药物、可卡因、苯二氮卓类药物、巴比妥类药物、苯环利定、美沙酮、三环类抗抑郁药等。
产品
- 设备
- 耗材和配件
根据产品，市场分为设备、消耗品和配件。
处方
- 柜台测试
- 基于处方的测试
根据处方模式，市场分为处方检测和非处方检测。
样品类型
- 尿
- 唾液
- 血
- 头发
- 气息
- 其他的
根据样本类型，市场分为尿液、唾液、血液、头发、呼吸和其他。
测试类型
- 随机测试
- 事故后测试
- 禁欲测试
根据测试类型，市场分为随机测试、事后测试和禁欲测试。
应用
- 医疗检查
- 工作场所筛查
- 执法和刑事司法
- 疼痛管理
- 药物滥用治疗和康复
- 家长或家庭药物检测
- 体育和田径测试
- 学校和教育机构的药物筛查
- 其他的
根据应用，市场分为医疗筛查、工作场所筛查、执法和刑事司法、疼痛管理、药物滥用治疗和康复、父母或家庭药物测试、运动和竞技测试、学校和教育机构的药物筛查等。
最终用户
- 医疗保健设施
- 雇主
- 政府机构
- 其他的
根据最终用户，市场分为医疗机构、雇主、政府机构和其他。
分销渠道
- 直接招标
- 零售销售
- 其他的
根据分销渠道，市场分为直接招标、零售销售和 其他。
北美即时诊断（POC）药物滥用检测市场区域分析/洞察
对北美即时诊断（POC）药物滥用检测市场进行了分析，并根据上述药物类型、产品、处方、样品类型、检测类型、应用、最终用户、分销渠道提供了市场规模洞察和趋势。
本市场报告涵盖的国家包括美国、加拿大和墨西哥。
由于人口众多、医疗支出高、医疗体系完善、制药业发达以及消费者对唇疱疹治疗的广泛认识和获取途径等因素，美国预计将在北美市场占据主导地位。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了区域品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和北美即时诊断（POC）药物滥用检测市场份额分析
北美即时诊断 (POC) 药物滥用检测市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、区域业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对北美即时诊断 (POC) 药物滥用检测市场的关注有关。
北美即时诊断（POC）药物滥用检测市场的主要参与者包括雅培实验室、Quest Diagnostics Incorporated、赛默飞世尔科技、Bio-rad Laboratories, inc.、安捷伦科技、Advacare Pharma 和 Cliawaived inc. 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING INCIDENCE OF DRUG ABUSE
5.1.2 GROWING EMPHASIS ON WORKPLACE SAFETY
5.1.3 GROWTH IN HOME AND PARENTAL DRUG TESTING KITS
5.1.4 RISING USE OF POC TESTING IN HEALTHCARE FACILITIES
5.2 RESTRAINTS
5.2.1 DATA SECURITY AND PRIVACY CONCERNS
5.2.2 LACK OF ACCURACY AND TECHNICAL CHALLENGES
5.3 OPPORTUNITIES
5.3.1 GROWING AWARENESS AND THE CAMPAIGN FOR DRUG TESTING
5.3.2 STRATEGIC INITIATION AND DECISION TAKEN BY THE MARKET PLAYERS
5.3.3 EXPANDING PRODUCT RANGE FOR POINT-OF-CARE DRUG ABUSE TESTING
5.4 CHALLENGES
5.4.1 LIMITED AWARENESS AND ACCEPTANCE
5.4.2 HIGH COSTS ASSOCIATED WITH THE TESTING
6 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE
6.1 OVERVIEW
6.2 AMPHETAMINES
6.3 OPIATES
6.4 CANNABINOIDS
6.5 COCAINE
6.6 BARBITURATES
6.7 BENZODIAZEPINES
6.8 METHADONE
6.9 PHENCYCLIDINE
6.1 TRICYCLIC ANTIDEPRESSANTS
6.11 OTHERS
7 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS
7.1 OVERVIEW
7.2 DEVICES
7.2.1 ANALYZER
7.2.1.1 IMMUNOASSAY ANALYZER
7.2.1.1.1 HIGH VOLUME
7.2.1.1.2 MID VOLUME
7.2.1.1.3 LOW VOLUME
7.2.1.2 BREATHALYZER
7.2.1.2.1 ELECTROCHEMICAL FUEL CELL BREATH ANALYZERS
7.2.1.2.2 INFRARED OPTICAL SENSOR BREATH ANALYZERS
7.2.1.2.3 SEMICONDUCTOR BREATH ANALYZERS
7.2.2 RAPID DEVICES
7.2.3 DRUG TESTING CASSETTE
7.2.4 DRUG TESTING CUPS
7.2.5 DIP CARDS/STRIPS
7.2.6 ORAL FLUID TESTING DEVICES
7.2.7 OTHERS
7.2.8 MODALITY
7.2.9 HANDHELD
7.2.10 MOBILE
7.2.11 MANUAL
7.2.12 AUTOMATED
7.3 CONSUMABLES AND ACCESSORIES
7.3.1 ASSAY KITS AND REAGENTS
7.3.2 PROBES
7.3.3 OTHERS
7.3.3.1 DAST-10
7.3.3.2 Plasma Protein Binding
7.3.3.3 Plasma and Serum Stability
7.3.3.4 Others
7.3.3.4.1 Multi-Panel Drug Test Kits
7.3.3.4.2 Single-Panel Drug Test Kits
8 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION
8.1 OVERVIEW
8.2 OVER THE COUNTER TESTING
8.3 PRESCRIPTION-BASED TESTING
9 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE
9.1 OVERVIEW
9.2 URINE
9.3 SALIVA
9.4 BLOOD
9.5 HAIR
9.6 BREATH
9.7 OTHERS
10 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE
10.1 OVERVIEW
10.2 RANDOM TESTING
10.3 POST-INCIDENT TESTING
10.4 ABSTINENCE TESTING
11 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 MEDICAL SCREENING
11.3 WORKPLACE SCREENING
11.4 LAW ENFORCEMENT AND CRIMINAL JUSTICE
11.5 PAIN MANAGEMENT
11.6 SUBSTANCE ABUSE TREATMENT AND REHABILITATION
11.7 PARENTAL OR HOME DRUG TESTING
11.8 SPORTS AND ATHLETICS TESTING
11.9 DRUG SCREENING IN SCHOOLS AND EDUCATIONAL INSTITUTIONS
11.1 OTHERS
12 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER
12.1 OVERVIEW
12.2 HEALTHCARE FACILITIES
12.2.1 HOSPITALS
12.2.2 EMERGENCY DEPARTMENT
12.2.3 CENTRAL LABS
12.2.4 CLINICS
12.2.5 POISON CONTROL CENTERS
12.2.6 OTHERS
12.3 EMPLOYERS
12.4 GOVERNMENT INSTITUTES
12.5 OTHERS
13 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.4 OTHERS
14 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 CANADA
14.1.3 MEXICO
15 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 SWOT ANALYSIS
17 COMPANY PROFILES
17.1 ABBOTT LABORATORIES
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 SIEMENS HEALTHINEERS AG
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 QUEST DIAGNOSTICS INCORPORATED
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 THERMO FISHER SCIENTIFIC INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 F.HOFFMAN-LA ROCHE LTD.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT UPDATES
17.5.6 RECENT UPDATES
17.6 ACCUBIOTECH CO., LTD.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
17.7 ADVACARE PHARMA
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT UPDATES
17.8 AGILENT TECHNOLOGIES, INC
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT UPDATES
17.9 ASSURE TECH (HANGZHOU) CO., LTD.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 BD
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 BEIJING HOTGEN BIOTECHN CO., LTD.
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 BIOEASY BIOTECHNOLOGY CO., LTD.,
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 BIO-RAD LABORATORIES, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 CLIAWAIVED, INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 DRUGSCAN
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 EGENS GROUP (NANTONG YISHI BIOTECHNOLOGY CO., LTD.)
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 HANGZHOU ALLTEST BIOTECH CO.,LTD
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 JOYSBIO (TIANJIN) BIOTECHNOLOGY CO., LTD
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT UPDATES
17.19 LIFESIGN LLC.
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 MERCK KGAA
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 MP BIOMEDICALS
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENT
17.22 PREMIER BIOTECH, INC.
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 SYSMEX CORPORATION
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENTS
17.24 WONDFO
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENT
17.25 XIAMEN BOSON BIOTECH CO., LTD.
17.25.1 COMPANY SNAPSHOT
17.25.2 PRODUCT PORTFOLIO
17.25.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 2 NORTH AMERICA AMPHETAMINES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 3 NORTH AMERICA OPIATES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 4 NORTH AMERICA CANNABINOIDS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 NORTH AMERICA COCAINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 6 NORTH AMERICA BARBITURATES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 7 NORTH AMERICA BENZODIAZEPINES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 8 NORTH AMERICA METHADONE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 9 NORTH AMERICA PHENCYCLIDINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 10 NORTH AMERICA TRICYCLIC ANTIDEPRESSANTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 11 NORTH AMERICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 12 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 13 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 15 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 16 NORTH AMERICA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 17 NORTH AMERICA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 18 NORTH AMERICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 19 NORTH AMERICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 20 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 21 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 22 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 24 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 25 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 26 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 27 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 28 NORTH AMERICA OVER THE COUNTER TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 29 NORTH AMERICA PRESCRIPTION-BASED TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 NORTH AMERICA URINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 32 NORTH AMERICA SALIVA IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 NORTH AMERICA BLOOD IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 NORTH AMERICA HAIR IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 NORTH AMERICA BREATH IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 NORTH AMERICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 38 NORTH AMERICA RANDOM TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 39 NORTH AMERICA POST-INCIDENT TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 NORTH AMERICA ABSTINENCE TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 41 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 42 NORTH AMERICA MEDICAL SCREENING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 NORTH AMERICA WORKPLACE SCREENING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 44 NORTH AMERICA LAW ENFORCEMENT AND CRIMINAL JUSTICE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 NORTH AMERICA PAIN MANAGEMENT IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 NORTH AMERICA SUBSTANCE ABUSE TREATMENT AND REHABILITATION IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 47 NORTH AMERICA PARENTAL OR HOME DRUG TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 48 NORTH AMERICA SPORTS AND ATHLETICS TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 49 NORTH AMERICA DRUG SCREENING IN SCHOOLS AND EDUCATIONAL INSTITUTIONS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 50 NORTH AMERICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 51 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 52 NORTH AMERICA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 53 NORTH AMERICA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 NORTH AMERICA EMPLOYERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 55 NORTH AMERICA GOVERNMENT INSTITUTES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 56 NORTH AMERICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 57 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 58 NORTH AMERICA DIRECT TENDER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 59 NORTH AMERICA RETAIL SALES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 60 NORTH AMERICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 61 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 62 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 63 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 64 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 66 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 67 NORTH AMERICA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 NORTH AMERICA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 NORTH AMERICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 NORTH AMERICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 71 NORTH AMERICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 72 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 73 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 74 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 77 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 78 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 79 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 80 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 81 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 83 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 84 NORTH AMERICA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 86 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 87 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 88 U.S. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 U.S. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 90 U.S. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 91 U.S. ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 U.S. IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 U.S. BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 94 U.S. BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 95 U.S. BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 96 U.S. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 97 U.S. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 98 U.S. CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 U.S. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 U.S. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 101 U.S. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 102 U.S. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 103 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 104 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 105 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 106 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 107 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 108 U.S. HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 109 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 110 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 111 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 112 CANADA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 CANADA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 114 CANADA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 115 CANADA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 116 CANADA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 CANADA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 118 CANADA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 119 CANADA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 120 CANADA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 121 CANADA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 122 CANADA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 123 CANADA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 CANADA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 125 CANADA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 126 CANADA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 127 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 128 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 129 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 131 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 132 CANADA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 134 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 136 MEXICO DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 MEXICO DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 138 MEXICO DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 139 MEXICO ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 140 MEXICO IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 141 MEXICO BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 142 MEXICO BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 143 MEXICO BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 144 MEXICO DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 145 MEXICO DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 146 MEXICO CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 147 MEXICO ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 148 MEXICO ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 149 MEXICO ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 150 MEXICO ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 151 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 152 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 153 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 154 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 155 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 156 MEXICO HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 157 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
图片列表
FIGURE 1 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: END USER COVERAGE GRID
FIGURE 8 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SEGMENTATION
FIGURE 11 TEN SEGMENTS COMPRISE THE NORTH AMERICA POINT-OF-CARE DRUG ABUSE TESTING MARKET, BY DRUG TYPE
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 RISING INCIDENCE OF DRUG ABUSE IS DRIVING THE GROWTH OF THE NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET FROM 2024 TO 2031
FIGURE 15 THE AMPHETAMINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOB POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET IN 2024 AND 2031
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET
FIGURE 17 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, 2023
FIGURE 18 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 19 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 20 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 21 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS 2023
FIGURE 22 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, 2024-2031 (USD THOUSAND)
FIGURE 23 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, CAGR (2024-2031)
FIGURE 24 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, LIFELINE CURVE
FIGURE 25 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, 2023
FIGURE 26 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, 2024-2031 (USD THOUSAND)
FIGURE 27 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, CAGR (2024-2031)
FIGURE 28 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, LIFELINE CURVE
FIGURE 29 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, 2023
FIGURE 30 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, 2024-2031 (USD THOUSAND)
FIGURE 31 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, CAGR (2024-2031)
FIGURE 32 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 33 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, 2023
FIGURE 34 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, 2024-2031 (USD THOUSAND)
FIGURE 35 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, CAGR (2024-2031)
FIGURE 36 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, LIFELINE CURVE
FIGURE 37 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, 2023
FIGURE 38 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, 2024-2031 (USD THOUSAND)
FIGURE 39 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 40 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 41 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, 2023
FIGURE 42 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 43 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, CAGR (2024-2031)
FIGURE 44 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 45 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 46 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 47 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 48 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 49 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SNAPSHOT (2023)
FIGURE 50 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY SHARE 2023 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
